The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Rick Sutin

Bioniche Signs Urocidin Deal with Endo Pharmaceuticals: $20 Million Up Front, $110 Million plus Supply to Follow

Exciting deal! Since Rick and I worked on this one, let me just turn it over to the press release:

Bioniche Life Sciences Inc. (TSX: BNC) and Endo Pharmaceuticals (Nasdaq: ENDP) jointly announced today that Endo has licensed from Bioniche the exclusive rights to develop and market Urocidin™ in the U.S. with an option for global rights. Urocidin is a patented formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed by Bioniche for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing. Under the agreement signed by both companies, Endo will pay Bioniche an up-front cash payment of $20M USD and the potential for up to $110M USD in additional payments linked to the achievement of future clinical, regulatory, and commercial milestones. In addition, Bioniche will manufacture the product and receive a transfer price for supply.

Update: Here it is on FierceBiotech.

Update 2: Here’s the BIO SmartBrief post.

Share Button

Follow

Get every new post delivered to your Inbox.

Join 126 other followers